Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

By afschroeder • October 7, 2025

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. J Cancer. 2025 Aug 11;16(13):3797-3809. doi: 10.7150/jca.117878. PMID: 41049010; PMCID: PMC12490977.

Tags: Checkpoint blockade, Combination immunotherapy, Hematology/Oncology, melanoma, Plozalizumab, Publications, Tovorafenib, Toxicities, vedolizumab

Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Konecny GE, Lim PC, Santin AD, Gilbert L, Alvarez Secord A, Bessette P, Matulonis UA, Sen J, Hong J, Lytle GE, Bako E, Spunt SL,[...]

Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply

O'Reilly EM, Wolpin BM, Wainberg ZA. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2026 Oct 22;395(16):1662. doi: 10.1056/NEJMc2611022. PMID: 42906097.

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Leshchiner I, Medford AJ, Cha J, Kiedrowski LA, Niemierko A, Keenan JC, Dai CS, Spring LM, Moy B, Wander SA, Vidula N, Isakoff SJ, Juric[...]